I fully endorse with the vision of author that further extensive clinical trials need to be performed involving population of other geographic areas and against other HIV strains prevalent in various continents before getting into a conclusion of preventive aspect of this vaccine against HIV as a whole. Its really raised eyebrows among scientific community since its a "medical breakthrough" in the advancement of HIV vaccine research. The alarming rise of HIV incidence as published in the August 6, 2008 issue of the Journal of the American Medical Association (JAMA), showed that in 2006, an estimated 56,300 new HIV infections occurred - a number that is substantially higher than the previous estimate of 40,000 annual new infections. Hence, the urgent need for vaccine against HIV infection is the need of hour and we hope that HIV vaccine will be made available very soon to halt this alarming situation.
Dr.S.Gunasakaran,MBBS,MD

Excellent article which addressed the hurldes in the implementataion of cervical cancer vaccination in developing country such as India. The availability of vaccine at an afforadable cost after the clinical trials involving Indian population seems to be promising to curtail the prevalence of preventable cervical cancer among Indian women.

Need for a booster dose after 6 years to preserve the efficacy of vaccine and other financial constraints for Indian Governement in the implemention of National Immunization Programme with cervical vaccine in India remains a challenge now.

Dr.S.Gunasakaran,MBBS,MD